Yervoy (ipilimumab) - BMS
Opdivo (nivolumab) - Ono Pharmaceutical, BMS
Tafinlar (dabrafenib) - Novartis
Mekinist (trametinib) - Novartis, BeOne Medicines
Management of oral stomatitis associated with BRAFi-MEKi therapy using intralesional corticosteroid and local anesthetic: a case report. (PubMed, Einstein (Sao Paulo)) - Sep 10, 2026 - "Nivolumab and ipilimumab were prescribed, but this combination was replaced with dabrafenib-trametinib due to disease progression. This report describes a previously unreported clinical presentation of an oral adverse event associated with combined BRAFi-MEKi therapy. It highlights the importance of recognizing unusual oral toxicities related to targeted therapies, as well as the role of appropriate local management in controlling symptoms and allowing the continuation of oncologic treatment." 
Journal • Anesthesia • Choroidal Melanomas • Dental Disorders • Melanoma • Ocular Melanoma • Oncology • Solid Tumor • Stomatitis
http://www.ncbi.nlm.nih.gov/pubmed/42715459
 
Alan Roger Santos-Silva; Aline Paim de Abreu Paulo Gomes; Aljomar José Vechiato-Filho; Ana Carolina Prado-Ribeiro; Ana Luiza Oliveira Corrêa Roza; André Caroli Rocha; João Gabriel Silva Souza; Julio Cesar Marcassa; Maria Cecília Querido de Oliveira; Maria Claudia Cuzzullin; Pablo Augustin Vargas; Vallentine Louzada Miranda
 
Sep 10, 2026
 
Prev Next